Incretin-Based Treatments as a New Approach to Managing Blood Pressure

Incretin-based therapeutics significantly lower blood pressure, especially in patients with obesity and hypertension.

• Recent studies indicate that glucagon-like peptide-1 receptor agonists and dual GLP-1/GIP receptor agonists may lead to substantial reductions in blood pressure.
• These therapies also promote weight loss, which is associated with improved blood pressure outcomes.
• Clinical evidence suggests that incretin-based treatments could enhance cardiovascular health in patients with hypertension.
• Current hypertension guidelines are urged to consider the benefits of incretin-based therapeutics for blood pressure management.
• No clinical trial has prioritized blood pressure reduction as the main outcome when assessing the effects of these therapies on antihypertensive medications.

Simplified